Document Detail

The interleukin-10 levels as a potential indicator of positive response to interferon beta treatment of multiple sclerosis patients.
MedLine Citation:
PMID:  16343740     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: Only a part of MS patients treated with interferon beta (IFN) respond positively to the applied treatment and to date no parameter predicting the response to treatment has been found. The aim of the study was to determine whether the levels of interleukin-10 and -12 (IL-10 and IL-12) might be the parameters enabling us to distinguish those patients who would best respond to therapy before the IFN treatment. PATIENTS AND METHODS: The study included 29 patients with clinically definite relapsing-remitting MS treated with IFN beta. In all of them the levels of IL-10 and IL-12 in blood serum and cerebrospinal fluid were determined before treatment using ELISA method. After the 2-year therapy the patients responding and nonresponding to IFN therapy were distinguished on the basis of clinical parameters. RESULTS: In the patients responding positively to IFN treatment the level of IL-10 in blood serum before treatment was found to be significantly lower (p<0.05) and distinctively differentiated responders from nonresponders. The IL-12 levels were similar both in cerebrospinal fluid and serum and no significant differences between responders and nonresponders were found. CONCLUSION: Our observations suggest that IL-10 level may be a useful parameter to identify the patients potentially responding to IFN therapy.
Halina Bartosik-Psujek; Zbigniew Stelmasiak
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2005-12-15
Journal Detail:
Title:  Clinical neurology and neurosurgery     Volume:  108     ISSN:  0303-8467     ISO Abbreviation:  Clin Neurol Neurosurg     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-09-25     Completed Date:  2007-01-05     Revised Date:  2009-10-14    
Medline Journal Info:
Nlm Unique ID:  7502039     Medline TA:  Clin Neurol Neurosurg     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  644-7     Citation Subset:  IM    
Department of Neurology, Medical University of Lublin, Lublin, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / analysis,  blood,  cerebrospinal fluid
Down-Regulation / drug effects,  immunology
Drug Resistance / immunology
Interferon-beta / therapeutic use*
Interleukin-10 / analysis,  blood*,  cerebrospinal fluid*
Interleukin-12 / analysis,  blood,  cerebrospinal fluid
Multiple Sclerosis / blood,  cerebrospinal fluid,  drug therapy*
Predictive Value of Tests
Treatment Outcome
Reg. No./Substance:
0/Biological Markers; 130068-27-8/Interleukin-10; 187348-17-0/Interleukin-12; 77238-31-4/Interferon-beta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  11Beta-hydroxysteroid dehydrogenase type 1: purification from human liver and characterization as ca...
Next Document:  Impact of genetic background on spontaneous or 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP...